Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Phase 3 Interventional Results available

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

NCT03200704
View directory record Official record
Conditions
Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Interventions
IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe
Combination Product
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients

NCT01789684
View directory record Official record
Conditions
Breast Cancer
Interventions
Active Provider Intervention
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
3,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 29, 2026, 2:34 AM EDT
Active, not recruiting Phase 1 Interventional

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678
View directory record Official record
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Early Phase 1 Interventional Results available

ICG and SLN Mapping

NCT05859971
View directory record Official record
Conditions
Breast Cancer
Interventions
SLN mapping using technetium-99m +/- isosulfan blue dye, SLN mapping with ICG fluorescence using the Asimov Platform
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated No phase listed Observational

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

NCT05068726
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
18F Fluoroestradiol Radiopharmaceutical with PET/CT
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Flagstaff, Arizona • Cerritos, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated Not applicable Interventional Results available

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00981578
View directory record Official record
Conditions
Bone Metastases
Interventions
ExAblate 2100
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs

NCT07038785
View directory record Official record
Conditions
Breast Cancer
Interventions
Breath test
Diagnostic Test
Lead sponsor
SpotitEarly
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Totowa, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Not listed Phase 2 Interventional

Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer

NCT00036998
View directory record Official record
Conditions
Breast Cancer
Interventions
conventional surgery, neoadjuvant therapy, thermal ablation therapy
Procedure
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Coral Springs, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 29, 2026, 2:34 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

NCT02436993
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Carboplatin, Paclitaxel, Bevacizumab, Trastuzumab, Pertuzumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer

NCT02590458
View directory record Official record
Conditions
Breast Cancer
Interventions
Short Breast MRI (SBMRI), Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional

Exercise to ReGain Stamina and Energy (The EXERGISE Study)

NCT05684367
View directory record Official record
Conditions
Fatigue, Breast Cancer, Cancer, Therapy-Related
Interventions
Center-Based Walking Exercise, Home-Based Walking Exercise
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 105 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Bundled Cancer Screening and Genetic Services Navigation

NCT07228000
View directory record Official record
Conditions
Breast Cancer Screening, Colon Cancer Screening, Genetics Predisposition
Interventions
Breast cancer screening navigation, Multicancer screening navigation, Usual care genetics referral, Pretest education + usual care genetics referral
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
45 Years to 74 Years · Female only
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Newark, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362
View directory record Official record
Conditions
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions
BT8009, Pembrolizumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
View directory record Official record
Conditions
Breast Cancer
Interventions
HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional

SAVE Trial: SAfe Opioid Use Video Education

NCT07044583
View directory record Official record
Conditions
Breast Reconstruction, Breast Cancer
Interventions
Opioid Educational Video
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

NCT01276041
View directory record Official record
Conditions
Breast Cancer
Interventions
pertuzumab in combination with trastuzumab and paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

NCT04190056
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Pembrolizumab, Tamoxifen, Vorinostat
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 29, 2026, 2:34 AM EDT
Completed No phase listed Observational Results available

Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

NCT01197456
View directory record Official record
Conditions
Breast Cancer, Ovarian Insufficiency, Ovarian Failure
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 29, 2026, 2:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

NCT00445445
View directory record Official record
Conditions
Breast Cancer
Interventions
physiologic testing, screening questionnaire administration, breast imaging study, radiomammography, study of high risk factors
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
2,201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
8
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio • Mentor, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 29, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects

NCT03897270
View directory record Official record
Conditions
Breast Carcinoma, Healthy Subject
Interventions
Photoacoustic Imaging
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437
View directory record Official record
Conditions
Breast Cancer
Interventions
ritonavir, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 29, 2026, 2:34 AM EDT
Completed No phase listed Observational

Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk

NCT00839696
View directory record Official record
Conditions
Breast Cancer Risk
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 70 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 29, 2026, 2:34 AM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00005873
View directory record Official record
Conditions
Breast Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 29, 2026, 2:34 AM EDT
Terminated Phase 1 Interventional

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

NCT01149356
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Exemestane, Gamma-Secretase Inhibitor RO4929097, Goserelin Acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 29, 2026, 2:34 AM EDT